8-K: Aptose Biosciences Acquired by Hanmi Pharma for C$2.41/Share

Aptose Biosciences Inc. has entered into a definitive arrangement agreement to be acquired by Hanmi Pharmaceuticals Co. Ltd. and its subsidiary HS North America Ltd. for C$2.41 per common share in cash.

Summary

• Aptose Biosciences Inc. (the "Company") has entered into a definitive arrangement agreement with Hanmi Pharmaceuticals Co. Ltd. ("Hanmi") and its wholly-owned subsidiary, HS North America Ltd. (the "Hanmi Purchasers").
• The Hanmi Purchasers will acquire all outstanding common shares of the Company not currently owned or controlled by them or their affiliates.
• Shareholders (excluding the Hanmi Purchasers and their affiliates) will receive C$2.41 in cash per common share.
• This consideration represents a premium of 28% over the Company's 30-day volume-weighted average price (VWAP) of C$1.88 on the Toronto Stock Exchange (TSX).
• The transaction involves a continuance of the Company under the Business Corporations Act (Alberta) and a subsequent plan of arrangement.
• Completion is subject to customary closing conditions, including court approval and approval by at least two-thirds (66 2/3%) of votes cast by shareholders and a majority of minority shareholders.
• The Company's Board of Directors, acting on the unanimous recommendation of a Special Committee of independent directors, unanimously determined the arrangement is in the best interests of the Company and fair to shareholders (excluding the Hanmi Purchasers).
• Directors and officers of the Company have entered into voting support agreements to vote their shares in favor of the transaction.
• All outstanding Incentive Securities (stock options and restricted share units) and Warrants will vest and be exchanged for cash at the Effective Time.
• A C$300,000 expense fee is payable to the Hanmi Purchaser if the arrangement agreement is terminated under certain circumstances, including a change in Board recommendation or a superior proposal.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for shareholders due to the significant premium offered and the certainty of a cash exit. The unanimous board recommendation further reinforces the positive outlook for the transaction's completion.

Positives

• Shareholders will receive a cash payment of C$2.41 per common share, representing a significant 28% premium over the 30-day VWAP.
• The transaction provides liquidity and certainty of value for Aptose shareholders.
• The Board of Directors and a Special Committee unanimously recommended the arrangement, indicating strong internal support.
• All outstanding Incentive Securities and Warrants will vest and be exchanged for cash, providing value to holders of these instruments.

Negatives

• The Company will cease to be an independent publicly traded entity, leading to delisting from the TSX and deregistration with the SEC.
• A C$300,000 expense fee is payable to the Hanmi Purchaser if the agreement is terminated under specific conditions, which could be a cost to Aptose if the deal falls through due to certain reasons.

Risks

• The transaction may not be completed on the terms and conditions, or on the timing, currently contemplated, or may not be completed at all.
• Failure to obtain or satisfy required regulatory, shareholder, and court approvals in a timely manner or otherwise.
• Risk that competing offers or acquisition proposals will be made.
• Negative impact on the price of the common shares if the transaction fails for any reason.
• Hanmi Purchaser's failure to pay the cash consideration at completion of the transaction.
• Significant business disruptions, including loss of employees due to transaction-related uncertainty, industry conditions, or other factors.
• Risks relating to employee retention.
• Risk of regulatory changes that may materially impact the business or operations of the Company.
• Diversion of management's attention from the Company's ongoing business operations while the transaction is pending.

Future Outlook

Following the completion of the transaction, Aptose Biosciences Inc. expects to no longer be subject to the reporting requirements of applicable Canadian securities legislation, and its common shares will be delisted from all stock exchanges where they are currently listed, including the TSX. The Purchaser intends to cause the Company to continue operating its business in a manner generally consistent with prior operations, subject to reasonable modifications.

Management Comments

• The Board, acting on the unanimous recommendation in favor of the Arrangement by the Special Committee and after receiving advice from its financial adviser and outside legal counsel, has unanimously determined that the Arrangement is in the best interests of the Company.
• The Board unanimously recommends that the Shareholders (other than the holders of the Excluded Shares) vote in favor of the Resolutions.
• Each of the directors and officers of the Company who owns Shares has advised the Company of their intention to vote or cause to be voted all Shares beneficially held by them in favor of the Arrangement Resolution.

Industry Context

This acquisition represents a strategic move by Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc., a company in the pharmaceutical/biotechnology sector. Such transactions are common in the industry, driven by factors like pipeline expansion, market access, or consolidation. The premium offered suggests Hanmi sees significant value in Aptose's assets or capabilities, aligning with broader trends of M&A activity in the life sciences for growth and innovation.

Comparison to Industry Standards

• The 28% premium offered over the 30-day VWAP is a strong indicator of value for shareholders, often exceeding typical premiums in similar-sized biotech acquisitions, which can range from 20-40% depending on the strategic fit and pipeline stage.
• The unanimous recommendation by the Board and Special Committee, supported by fairness opinions and formal valuations, aligns with best practices for corporate governance in M&A transactions, ensuring shareholder interests are considered.
• The requirement for both overall shareholder approval (2/3) and minority shareholder approval (majority excluding Hanmi) is a robust governance standard, particularly in Canada, designed to protect non-insider shareholders in related-party transactions.

Management Changes

Corporate Governance

Legal Proceedings

• The completion of the transaction is conditional on no legal action being commenced that would cease trade, enjoin, or prohibit the acquisition, or impose limitations on Hanmi's ownership rights, or materially delay the arrangement.
• Aptose Biosciences Inc. is required to obtain an agreement from CrystalGenomics, Inc. confirming the termination of the CG-806 license, the non-existence of any cause of action, and a customary mutual release of claims.

Related Party Transactions

• Hanmi Pharmaceuticals Co. Ltd. and its wholly-owned subsidiary HS North America Ltd. are the acquirers, and Hanmi already beneficially owns 508,710 shares of Aptose Biosciences Inc.
• A Debt Conversion and Interest Payment Agreement exists between Aptose Biosciences Inc. and Hanmi Pharmaceuticals Co. Ltd. dated August 27, 2024.
• A New Facility Agreement exists among Aptose Biosciences Inc., Aptose Biosciences U.S. Inc., NuChem Pharmaceuticals Inc., and Hanmi Pharmaceuticals Co. Ltd. dated June 18, 2025.
• An Investor Rights Agreement exists between Aptose Biosciences Inc. and Hanmi Pharmaceuticals Co. Ltd. dated September 26, 2023.
• Voting support agreements have been entered into between HS North America Ltd. and the directors and officers of Aptose Biosciences Inc. who own shares.

Stakeholder Impact

• Shareholders: Will receive C$2.41 in cash per common share, representing a 28% premium, providing a clear and immediate return on investment. They will no longer hold shares in a publicly traded entity.
• Employees: Will receive total compensation (excluding incentive plans) that is substantially similar for 12 months post-acquisition. Termination and severance benefits will be no less favorable than existing plans or legal requirements. Employee benefits will be comparable in aggregate (excluding defined benefit, equity, or retiree health/welfare). There is no guarantee of continued employment.
• Management: Directors and officers have committed to supporting the transaction through voting agreements. There will be customary resignations and replacements of directors at the Effective Time.
• Creditors: The existing financial agreements with Hanmi Pharmaceuticals Co. Ltd. (Parent) are part of the related-party context of this acquisition, and the transaction will impact the Company's overall financial structure.

Next Steps

• Aptose Biosciences Inc. will apply for an Interim Order from the Court of Kings Bench of Alberta.
• The Company will prepare and file a preliminary and definitive Proxy Statement/Circular with the SEC and on SEDAR+.
• A Special Meeting of Shareholders will be convened no later than January 16, 2026, to vote on the Continuance Resolution and the Arrangement Resolution.
• Following shareholder approval, the Company will apply for a Final Order from the Court.
• The closing of the transaction, including the filing of Articles of Arrangement, will occur as soon as reasonably practicable (within 5 business days) after all conditions are satisfied or waived.
• The Company's shares will be delisted from the TSX and the Company will cease to be a reporting issuer under Canadian securities laws and deregister with the SEC.
• Hanmi Purchaser will file its notification under the Foreign Exchange Transactions Act (Korea) within 15 business days of the agreement date.
• Aptose Biosciences Inc. will use reasonable best efforts to obtain an agreement from CrystalGenomics, Inc. regarding the termination of the CG-806 license and a mutual release of claims.
• Aptose Biosciences Inc. will use reasonable best efforts to obtain Support and Voting Agreements from shareholders holding at least 5% of the Shares within 10 days following the mailing of the Circular.

Key Dates

Keywords

Acquisition, Merger, Biotechnology, Pharmaceuticals, SEC Filing, Arrangement Agreement, Shareholder Approval, Delisting, Hanmi Pharmaceuticals, Aptose Biosciences, Cash Offer, Premium